Table 1.
Patient characteristics dichotomized by immunoglobulin free light chain (FLC)
|
Percent of patients
|
||||
|---|---|---|---|---|
| Baseline characteristic | All | Baseline FLC < 152 mg/L | Baseline FLC ≥ 152 mg/L | P |
| Male | 59 | 60 | 58 | .79 |
| Clonality, λ | 74 | 75 | 72 | .96 |
| Prior therapy | 36 | 43 | 29 | .10 |
| Kidney involvement | 68 | 72 | 64 | .40 |
| Heart involvement | 51 | 45 | 58 | .17 |
| Liver involvement | 18 | 19 | 17 | .97 |
| Peripheral nerve involvement | 17 | 18 | 15 | .65 |
| Autonomic nerve involvement | 7 | 7 | 7 | .98 |
| Other organ involvement* | 27 | 21 | 43 | .034 |
| Reduced conditioning intensity† | 24 | 15 | 32 | .028 |
| Year of PBSCT 1996-2002 | 41 | 43 | 39 | .63 |
There were 60 patients with baseline FLC below 152 mg/L and 59 with baseline FLC at or above 152 mg/L. FLC indicates involved immunoglobulin free light chain.
Other includes 15 patients microvascular (claudication); 17 patients gastrointestinal; 3 patients pulmonary; 2 patients myopathy; and 1 patient factor X deficiency with splenic rupture. Total does not add up to 35 because patients had more than one type of involvement
Melphalan 100 mg/m2 to 140 mg/m2 without total body irradiation